APA (7th ed.) Citation

Xu, Y., Zhang, Y., Jin, H., Zhong, H., Xu, J., Lou, Y., & Zhong, R. Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Xu, Yingqi, Yidan Zhang, Hongping Jin, Hua Zhong, Jianlin Xu, Yuqing Lou, and Runbo Zhong. Comparison of First-generation EGFR-TKIs Combined with Low-dose Bevacizumab Versus Osimertinib in Untreated Advanced EGFR-mutated NSCLC. Taylor & Francis Group.

MLA (9th ed.) Citation

Xu, Yingqi, et al. Comparison of First-generation EGFR-TKIs Combined with Low-dose Bevacizumab Versus Osimertinib in Untreated Advanced EGFR-mutated NSCLC. Taylor & Francis Group.